Britannia Life Sciences Inc. offers product testing, safety assessment, and compliance services primarily for the cosmetics and nutraceutical sectors. Its financial health is strong, highlighted by an impressive EBITDA margin of 1201.9% and a current ratio of 5.69, indicating robust liquidity. However, the gross margin of 19.2% raises concerns about profitability relative to its high margins elsewhere. The low market cap of $11.36M suggests potential undervaluation despite solid financial metrics, warranting further investigation into growth prospects and market positioning.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Strong gross margin of 59.7% reflects healthy unit economics.
Fortress balance sheet: cash covers total debt 56×, providing significant financial flexibility.
Excellent liquidity with current ratio of 5.7x ensures operational stability.
Low debt-to-revenue ratio of 25.9% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q1 (June 30, 2026)